LLY241213P490000
- 0.00
- 0.000.00%
Eli Lilly and Co Newsroom
Market Mixed on Friday the 13th | Livestock
Eli Lilly's Mounjaro Won't Have Separate Indication for Obstructive Sleep Apnea, European Regulator Says
EMA: Eli Lilly and Co (LLY.US) weight loss drug Mounjaro can also treat sleep apnea without the need for additional indications.
An expert panel of the EU pharmaceutical regulatory institution EMA has determined that Eli Lilly and Co's weight-loss drug Mounjaro does not require a separate indication for the treatment of obstructive sleep apnea (OSA).
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Eli Lilly Gets Key European Backing for Omvoh in Crohn's Disease
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Express News | Eli Lilly and Co - European Commission Decision on Omvoh Expected in Next 1-2 Months
Express News | Eli Lilly and Co - Expects U.S. Decision on Omvoh for Crohn's Disease in H1 2025
Express News | Lilly's Omvoh® (Mirikizumab) Recommended by Chmp for Approval in the European Union for Adults With Moderately to Severely Active Crohn's Disease
Express News | EMA's Chmp: Finalised Assessment of Application to Extend Use of Mounjaro to Include Treatment of Obstructive Sleep Apnoea in Adults With Obesity
Eli Lilly and Co (LLY.US) Mounjaro has replaced Novo-Nordisk A/S (NVO.US) Wegovy as the new favorite weight loss drug in the United Kingdom.
The number of private individuals in the United Kingdom purchasing weight loss drugs is continuously increasing, with Eli Lilly and Co's Mounjaro gradually surpassing Novo-Nordisk A/S's Wegovy, becoming a new favorite among consumers.
Lilly's Omvoh (Mirikizumab) Recommended by CHMP for Approval in the European Union for Adults With Moderately to Severely Active Crohn's Disease
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
Thursday Ends in Index Declines | Wall Street Today
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
"Person of the Year" Trump rings the opening bell at the NYSE, emphasizing that "the stock market is everything."
On December 12, the elected President Trump was named Time Magazine's Person of the Year for 2024, ringing the opening bell at the NYSE that day; Trump rang the bell with the CEO of ICE and the CEO of Time Magazine, along with the president of the NYSE, while the CEOs of companies such as Goldman Sachs and Citigroup were present; Trump promised an "unprecedented economy," planned to increase oil drilling to reduce inflation, and committed to lowering the corporate tax rate to 15%.
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound